Citi analyst Samantha Semenkow lowered the firm’s price target on Argenx (ARGX) to $1,091 from $1,124 and keeps a Buy rating on the shares. The firm says its neurologist survey shows the Vyvgart launch continues to gain momentum. Citi says Argenx is a top pick for 2026. The target drop reflects a model update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to EUR 880 from EUR 850 at Barclays
- Immunovant upgraded to Outperform at Wolfe on improving Graves’ perception
- argenx: Leadership Continuity and Pipeline Milestones Underpin Sustained Buy Rating and $1,006 Price Target
- argenx: Leadership Transition, Pipeline Strength, and Commercial Expansion Support Buy Rating and $915 Target
- Argenx Unveils CEO Succession as Co‑Founder Moves to Chair Role